Cannabics Pharmaceuticals Inc., an international leader developing cancer-related cannabinoid-based drugs, headquartered in Maryland, United States, announced on Wednesday, July 07, that it had welcomed Dr. Inbar Maymon-Pomeranchik company’s Board of directors table as an Independent Director.
Dr. Maymon-Pomeranchik is a highly trained professional with expertise in molecular and genetic research. He holds a Ph.D. from Hebrew University and has approximately 20 years of executive-level experience in biotechnology sciences with particular professional expertise in the global medical cannabis industry. Dr. Maymon-Pomeranchik serves as a board member for multiple public firms and companies.
She is particularly thrilled with its plans to seek FDA approval for its expanding pipeline of promising drug candidates.The technology-driven drug development company has its R&D facility set up in Israel. The Cannabics Pharmaceutical facility in Israel is licensed by the Ministry of Health, permitting them to conduct science and clinical research on Cannabics formulations.
Be First to Comment